Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455988 | 1.00 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1639503 | 0.86 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1640187 | 0.85 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1639645 | 0.84 | HRH3 (0.73) | KCNH2HRH3 | |
| SCHEMBL1641173 | 0.84 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL6250516 | 0.84 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1641306 | 0.84 | KCNH2 (0.73) | KCNH2HRH3 | |
| SCHEMBL1640946 | 0.84 | KCNH2 (1.00) | KCNH2HRH3 | |
| SCHEMBL1641292 | 0.84 | KCNH2 (0.73) | KCNH2HRH3 | |
| SCHEMBL1639446 | 0.84 | KCNH2 (0.76) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258703-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-7205316-B2 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | claimed |
| EP-1751130-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | claimed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | claimed |
| EP-2258703-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7205316-B2 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1751130-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | KCNH2 1109/4885HRH3 1/4885 |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | KCNH2 1109/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.